+Compare
ABBV
Stock ticker: NYSE
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
272.96B

ABBV ABBVIE Forecast, Technical & Fundamental Analysis

a research-based pharmaceutical company

Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for ABBV with price predictions
08:00 PM EDT Sep 24, 2023

ABBV in -0.57% downward trend, declining for three consecutive days on September 22, 2023

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where ABBV declined for three days, in of 248 cases, the price declined further within the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for ABBV moved out of overbought territory on September 15, 2023. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 44 similar instances where the indicator moved out of overbought territory. In of the 44 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 11 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

ABBV broke above its upper Bollinger Band on September 13, 2023. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on September 07, 2023. You may want to consider a long position or call options on ABBV as a result. In of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for ABBV just turned positive on September 13, 2023. Looking at past instances where ABBV's MACD turned positive, the stock continued to rise in of 46 cases over the following month. The odds of a continued upward trend are .

The 50-day moving average for ABBV moved above the 200-day moving average on September 22, 2023. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ABBV advanced for three days, in of 365 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 320 cases where ABBV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 67, placing this stock better than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ABBV's P/B Ratio (20.964) is slightly higher than the industry average of (6.139). P/E Ratio (31.447) is within average values for comparable stocks, (31.865). Projected Growth (PEG Ratio) (6.062) is also within normal values, averaging (3.317). Dividend Yield (0.038) settles around the average of (0.028) among similar stocks. P/S Ratio (4.843) is also within normal values, averaging (3.735).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ABBV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), Merck & Co (NYSE:MRK), AstraZeneca PLC (NASDAQ:AZN), Pfizer (NYSE:PFE), Amgen (NASDAQ:AMGN), Bristol-Myers Squibb Co (NYSE:BMY), Gilead Sciences (NASDAQ:GILD), Biogen (NASDAQ:BIIB).

Industry description

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

Market Cap

The average market capitalization across the Pharmaceuticals: Major Industry is 80.53B. The market cap for tickers in the group ranges from 72.83K to 524.29B. LLY holds the highest valuation in this group at 524.29B. The lowest valued company is CRXTQ at 72.83K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Major Industry was -2%. For the same Industry, the average monthly price growth was -3%, and the average quarterly price growth was -1%. AZNCF experienced the highest price growth at 4%, while SCLX experienced the biggest fall at -17%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Major Industry was -11%. For the same stocks of the Industry, the average monthly volume growth was -1% and the average quarterly volume growth was 7%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 28
P/E Growth Rating: 59
Price Growth Rating: 57
SMR Rating: 57
Profit Risk Rating: 66
Seasonality Score: -17 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I. Advisor
published Earnings

ABBV is expected to report earnings to fall 1.03% to $2.88 per share on November 03

ABBVIE ABBV Stock Earnings Reports
Q3'23
Est.
$2.88
Q2'23
Beat
by $0.04
Q1'23
Est.
$2.46
Q4'22
Beat
by $0.07
Q3'22
Beat
by $0.08
The last earnings report on July 27 showed earnings per share of $2.91, beating the estimate of $2.87. With 3.74M shares outstanding, the current market capitalization sits at 272.96B.
A.I.Advisor
published Dividends

ABBV paid dividends on August 15, 2023

ABBVIE ABBV Stock Dividends
А dividend of $1.48 per share was paid with a record date of August 15, 2023, and an ex-dividend date of July 13, 2023. Read more...
A.I. Advisor
published General Information

General Information

a research-based pharmaceutical company

Industry PharmaceuticalsMajor

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
1 North Waukegan Road
Phone
+1 847 932-7900
Employees
50000
Web
http://www.abbvieinvestor.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SFM42.160.78
+1.88%
Sprouts Farmers Market
CODX1.060.01
+0.95%
Co-Diagnostics
CTAS505.520.77
+0.15%
Cintas Corp
ECPG45.770.07
+0.15%
Encore Capital Group
FBIZ29.62-0.13
-0.44%
First Business Financial Services

ABBV and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABBV has been loosely correlated with PFE. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if ABBV jumps, then PFE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABBV
1D Price
Change %
ABBV100%
+1.25%
PFE - ABBV
54%
Loosely correlated
+0.89%
MRK - ABBV
49%
Loosely correlated
-0.47%
JNJ - ABBV
43%
Loosely correlated
-0.15%
AMGN - ABBV
43%
Loosely correlated
-0.31%
AZN - ABBV
40%
Loosely correlated
+1.64%
More

Groups containing ABBV

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABBV
1D Price
Change %
ABBV100%
+1.25%
diseases
(undefined stocks)
46%
Loosely correlated
-1.36%
growing dividends
(undefined stocks)
35%
Loosely correlated
+0.46%
pharmaceuticals
(undefined stocks)
35%
Loosely correlated
-0.92%
Pharmaceuticals: Major
(undefined stocks)
28%
Poorly correlated
-0.03%
small molecule
(undefined stocks)
28%
Poorly correlated
+0.82%
More